Navigation Links
Wisconsin won't get Georgia biotech without a fight

Madison, Wis. - Wisconsin officials and investors who are trying to come up with the financing that will enable a Georgia life science firm to relocate here have a fight on their hands.

And that's because Georgia is not simply willing to let go of Aruna Biomedical, an Athens, Ga. business that produces neural stem cell kits for researche......

Full article >>> genitors and the reagents needed to both proliferate and differentiate them into cultures of neural cells. The cells and proliferation media are used by biomedical researchers looking to develop therapies for neurological diseases and spinal cord injuries.

One of the reasons the company would relocate to Wisconsin is to take advantage of synergies from stem cell research at the Ernst & Young, LLP and Dow Jones Venture CapitalOne. Wisconsin also raised $19 million in angel investments in 2005, according to NorthStar Economics, Inc.

Both state gov......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 02/06/07


Related biology technology :

1. To be a player in the "Knowledge Economy," Wisconsin needs more tech workers
2. Federal bioenergy lab will give Wisconsin a chance to shine
3. Breaking down Wisconsins angel capital numbers
4. Innovation featured in NE Wisconsin Roundtable
5. Visions: Broderick says Wisconsin should be in top third in venture capital
6. Wisconsin building toward the major leagues of venture capital
7. Wisconsin Supreme Court to hear Menasha software case
8. Wisconsin applicants urged to pursue DOE funding for cellulosic biomass
9. Legislature should look to Wisconsins natural energy advantages
10. Stem cells get most attention, but they are only part of Wisconsins bio-portfolio
11. BIO 2007: Wisconsin makes its presence felt
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... March 23, 2017 In today,s ... equities in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: ... (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market ... free report at: ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... LEXINGTON, Mass. , March 22, 2017   ... collections, today announced that Doctors Pathology Service ... mid-Atlantic region of the United States ... the Delaware Health Information Network (DHIN) to ... researchers. The novel program, announced in ...
Breaking Biology Technology:
(Date:3/16/2017)... March 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... Used combined in one ... ...
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
Breaking Biology News(10 mins):